GTCR to Acquire Surmodics for $43.00 per Share; Equity Value Approximately $627M

Surmodics Acquires Alta Biomed to Expand Medical Device Coating and Testing Capabilities

October 2, 2026

Medical Devices

Surmodics acquired the business of Alta Biomed to expand its portfolio of hemocompatible and biocompatible surface technologies, including the proprietary PzF thin-film surface modification technology. The deal also adds specialized analytical testing capabilities for blood- and tissue-contacting medical devices at Alta Biomed’s Carlsbad, California facility.

Surmodics Merges with Biocoat; Forms Surmodics Services & Technologies Division

December 10, 2025

Medical Devices

Surmodics has completed a merger with Biocoat and formed a new division, Surmodics Services & Technologies (SST), to carry forward the portion of Biocoat's business remaining after divesting certain assets. SST, based in Horsham, Pennsylvania, will provide hydrophilic coating technologies, custom polymer formulations and full-service coating operations to medical device manufacturers worldwide.

GTCR Affiliate Acquires Surmodics, Inc.

November 10, 2025

Medical Devices

Surmodics announced that a U.S. district court denied the FTC and certain state regulators’ request for a preliminary injunction to block the company’s proposed acquisition by an affiliate of GTCR. Surmodics said the merger remains subject to a temporary restraining order and customary closing conditions, with the company expecting to move toward closing promptly.

GTCR Announces $200M Strategic Minority Investment in Solmetex

October 15, 2025

Dental

GTCR has made a structured minority investment of up to $200 million in Solmetex to fund the company's growth initiatives and support near-term add-on acquisitions. GTCR will partner with existing shareholders including AGIC Capital and Solmetex CEO Gene Dorff to scale the company's dental products and consumables business serving more than 85,000 U.S. dental practices.

Surmodics Acquires Vetex Medical Limited

July 6, 2021

Medical Devices

Surmodics, Inc. (NASDAQ: SRDX) acquired Galway-based Vetex Medical Limited to expand its thrombectomy portfolio with the ReVene Thrombectomy Catheter. The deal included an upfront payment of $39.9 million and up to $7 million in additional milestone payments (with $3.5 million guaranteed), giving Surmodics a second FDA 510(k)-cleared mechanical thrombectomy device and IP to accelerate its thrombectomy platform development.

Gilead Sciences Acquires Immunomedics

September 13, 2020

Biotechnology

Gilead Sciences agreed to acquire Immunomedics for $88.00 per share in an all-cash transaction valuing Immunomedics at approximately $21 billion. The acquisition gives Gilead global rights (outside certain Asian territories) to Trodelvy, an FDA‑approved antibody‑drug conjugate for metastatic triple‑negative breast cancer, and accelerates Gilead’s expansion into oncology.